Cytokinetics
CYTK
134 hedge funds and large institutions have $315M invested in Cytokinetics in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 46 reducing their positions, and 21 closing their positions.
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
2% more funds holding
Funds holding: 132 → 134 (+2)
7% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 46
2.32% less ownership
Funds ownership: 73.92% → 71.59% (-2.3%)
38% less call options, than puts
Call options by funds: $1.24M | Put options by funds: $1.99M
45% less capital invested
Capital invested by funds: $575M → $315M (-$261M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$50.9M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$11.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10M |
| 4 |
BlackRock
New York
|
+$4.47M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$40.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.4M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.33M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$7.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | -74 | Closed |
|
152
SEI Investments
Oaks,
Pennsylvania
| – | +$159 | +14 | New |
|
153
AssetMark Inc
Concord,
California
| – | +$170 | +15 | New |
|
CYTK Hedge Fund Activity: Q4 2017 in Review
134 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2017, worth a combined $315M — down 45% from $575M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CYTK positions and 21 closed out — a net gain of 3 holders — while 43 added to existing stakes and 46 trimmed.
The largest buyer was BVF Inc, adding an estimated $50.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $40.3M sold.
- 134 institutional investors held Cytokinetics (CYTK) as of Q4 2017, up from 132 in Q3 2017.
- Funds reported $315M of Cytokinetics stock for Q4 2017, down 45% quarter-over-quarter.
- 24 funds opened new Cytokinetics positions in Q4 2017 and 21 closed out, a net change of +3 holders.
- The largest Cytokinetics buyer in Q4 2017 was BVF Inc, an estimated $50.9M added.
- The largest Cytokinetics seller in Q4 2017 was Janus Henderson Group, an estimated $40.3M sold.
Based on aggregated 13F filings for Q4 2017.